Internal Discovery Programs
Hematological and solid tumor cancers, Neurodegenerative diseases
Key Facts
About Interdict
Interdict Bio is a private, pre-clinical stage biotech founded in 2022 and based in Cambridge, USA, developing a revolutionary small molecule modality called Interdictors™. Its platform targets the ribosome to selectively inhibit the synthesis of pathogenic proteins, enabling it to address validated but elusive targets like intrinsically disordered proteins (e.g., MYC) and aggregation-prone proteins. The lead program targeting MYC-dependent cancers is in IND-enabling studies, positioning the company to potentially open new therapeutic frontiers in oncology and neurodegeneration.
View full company profileAbout NeuCyte
NeuCyte is a private, pre-revenue biotech founded in 2015 and based in Sunnyvale, California, with a core focus on neurological diseases. Its primary asset is the SynFire® platform, which produces homogeneous, high-functioning iPSC-derived neurons, astrocytes, and microglia for use in phenotypic screening and target-based drug discovery. The company operates with a hybrid business model, pursuing internal drug discovery programs while offering its platform and cells for strategic partnerships to external biopharma clients. NeuCyte is at a pre-clinical stage, utilizing its technology to identify novel therapeutic candidates and de-risk the early-stage neuroscience R&D process.
View full company profile